Browse the evidence

Bariatric surgery is the most efficacious treatment for sustained weight loss and can induce long-term remission of type 2 diabetes in approximately 30% of patients, with Roux-en-Y gastric bypass being potentially more effective than sleeve gastrectomy for T2D remission.

For severe obesity, bariatric surgery is the most effective long-term treatment. It can lead to remission of type 2 diabetes in about 30% of patients and reduces the risk of heart disease and stroke. It is a serious medical intervention, not a cosmetic procedure.

Elevated baseline plasma ceramide concentrations are positively associated with an increased risk of incident cardiovascular disease (CVD), including myocardial infarction, stroke, and cardiovascular death.

High plasma ceramide levels are linked to a higher risk of heart attacks, strokes, and cardiovascular death. However, this risk is not fixed; adhering to a Mediterranean diet (enriched with olive oil or nuts) can neutralize the increased risk associated with high ceramide levels, bringing it down to the level of those with low ceramide levels.

In healthy humans, disuse-induced muscle atrophy is primarily driven by a significant reduction in muscle protein synthesis (MPS), while muscle protein breakdown (MPB) remains largely unchanged.

If you are immobilized or inactive but healthy, your muscle loss is not because your body is actively destroying muscle tissue, but because it has stopped building it. The primary lever to prevent loss is to restore the stimulus for muscle protein synthesis (e.g., through resistance exercise or adequate protein intake) rather than focusing solely on preventing breakdown.

In disease states (e.g., sepsis, cancer, critical illness), muscle atrophy is driven by both elevated muscle protein breakdown (MPB) and reduced muscle protein synthesis (MPS), mediated by inflammatory cytokines.

If you have a disease involving inflammation (like cancer or sepsis), your muscle loss is driven by both increased breakdown and decreased synthesis due to inflammatory signals. Preventing loss requires addressing the underlying disease and inflammation, not just rest or exercise.

In overweight or obese individuals with type 2 diabetes, metabolic dyslipidemia (defined as high triglycerides and low HDL-C) is associated with a significantly higher risk of coronary artery disease and composite cardiovascular events, independent of LDL-C levels.

If you have Type 2 Diabetes and are overweight, your risk of heart disease is significantly higher if you have both high triglycerides and low HDL cholesterol, even if your LDL is normal. This risk exists independently of your LDL levels. You should discuss your triglyceride and HDL levels with your doctor as part of your cardiovascular risk assessment, not just your LDL.

Bariatric surgery significantly reduces the overall incidence of cancer, obesity-related cancers, and cancer-associated mortality in patients with morbid obesity compared to conventional treatment.

For individuals with morbid obesity, bariatric surgery is a highly effective intervention for reducing the risk of developing various cancers, particularly obesity-related types like breast, colorectal, and endometrial cancer, as well as reducing cancer mortality. This benefit is attributed to sustained weight loss and metabolic improvements that are difficult to achieve through lifestyle changes alone.

Bariatric surgery significantly reduces the incidence of specific obesity-related cancers, including hepatocellular, colorectal, pancreatic, gallbladder, breast, endometrial, and ovarian cancers.

Bariatric surgery offers significant protection against several specific types of cancer, particularly those linked to obesity and hormones (breast, endometrial, ovarian) and metabolic factors (liver, colorectal, pancreatic, gallbladder).

Lifestyle interventions alone are often insufficient for long-term weight maintenance due to hormonal and metabolic adaptations that drive weight regain, necessitating adjunctive therapies for many patients.

If you regain weight after lifestyle changes, do not blame yourself. Your body's hormones and metabolism are adapting to store energy. This is a common biological response, and it is why medical guidelines recommend considering additional therapies (like medication) if lifestyle changes alone do not sustain your results.

Sulfonylureas are associated with weight gain, hypoglycemia, and declining long-term efficacy, making them unsuitable as first- or second-line treatments.

Avoid sulfonylureas if possible. They cause weight gain and low blood sugar, and their effectiveness fades over time. Use them only if other, safer options are not available or affordable.

Adipose tissue (AT) dysfunction, rather than fat mass alone, is the primary mechanistic link between obesity and adverse health outcomes, explaining why some individuals with obesity remain metabolically healthy while others with normal weight develop obesity-related diseases.

Your health risk from obesity is not just about how much you weigh, but how your fat tissue is functioning. Factors like visceral fat, inflammation, and insulin sensitivity matter more than BMI alone. Focus on metabolic health markers rather than just the scale.

Long-acting GLP-1 receptor agonists (liraglutide and semaglutide) activate POMC neurons and inhibit NPY/AgRP neurons in vivo, with effects occurring 12-24 hours post-injection and dependent on the TRPC5 channel and metabolic state.

Long-acting GLP-1 drugs like liraglutide and semaglutide change brain activity related to hunger and energy use, but this happens slowly, peaking 12-24 hours after injection. This effect is stronger when you are fasting. The drug works by activating specific brain cells (POMC) that reduce hunger and inhibiting others (NPY/AgRP) that increase it, using a channel called TRPC5.

Gut peptides such as GLP-1 and PYY, along with vagal afferent signaling, play a critical role in homeostatic appetite suppression and satiety signaling.

Your gut produces hormones like GLP-1 and PYY when you eat, which signal your brain to stop eating. This is a natural biological process. Understanding this can help explain why certain foods or eating patterns might affect your satiety levels.

Adipocyte ATP-citrate lyase (ACLY) is essential for handling dietary carbohydrates and maintaining metabolic homeostasis in females, as its deficiency leads to lipodystrophy-like phenotypes, hepatic steatosis, and insulin resistance when consuming high-carbohydrate diets.

For women, high-carbohydrate diets may pose a higher metabolic risk if adipose tissue function is compromised, potentially leading to fat storage in the liver and insulin resistance. Men may tolerate similar carbohydrate loads better. This suggests that women might benefit from monitoring carbohydrate quality and quantity more closely, especially if they have underlying metabolic vulnerabilities.

Brainstem cholecystokinin-expressing (CCKAP/NTS) neurons are required for the appetite-suppressing and body-weight-lowering effects of GLP-1 receptor agonists.

GLP-1 medications like semaglutide or liraglutide work by activating specific neurons in the brainstem (CCK neurons). If these neurons are blocked or non-functional, the medication will not suppress appetite or reduce body weight. This highlights that the drug's efficacy depends on this specific neural pathway.

GIP receptor activation reduces the recruitment of CCKAP/NTS neurons and selectively reduces conditioned taste avoidance without abolishing weight loss.

Adding GIP receptor activation to GLP-1 therapy reduces the activation of brainstem neurons responsible for nausea, thereby reducing side effects like nausea without significantly compromising the weight-loss benefits. This suggests dual-agonists may offer a better tolerability profile.

Higher intake of unprocessed red meat and total meat is associated with a significantly higher incidence of atherosclerotic cardiovascular disease (ASCVD) in older adults, partly mediated by gut microbiota-derived metabolites TMAO, gamma-butyrobetaine, and crotonobetaine.

If you are over 65, be mindful of your red meat consumption. This study links higher intake of unprocessed red meat and total meat to a higher risk of heart disease and stroke. The risk is partly explained by how gut bacteria process compounds in red meat into substances like TMAO. You don't need to eliminate red meat entirely, but balancing it with fish, poultry, and plant-based proteins may help lower your cardiovascular risk.

Intensive glucose-lowering strategies significantly increase the risk of severe hypoglycemia compared to standard therapy.

If you are on intensive diabetes treatment to lower your blood sugar significantly, be aware that your risk of severe low blood sugar (hypoglycemia) nearly doubles compared to standard treatment. This risk must be weighed against the benefits for your eyes and kidneys. Regular monitoring and awareness of hypoglycemia symptoms are crucial.

Pioglitazone improves NASH histology without worsening fibrosis in patients with T2DM and MAFLD, but its use is limited by side effects including weight gain, fluid retention, and potential bladder cancer risk.

Pioglitazone (45mg daily) can improve liver inflammation (NASH) in people with type 2 diabetes and fatty liver without worsening scarring. However, it can cause weight gain, fluid retention, and may increase the risk of bladder cancer in some people. It is not recommended for everyone and should be used with caution, especially if you have a history of heart failure or bladder cancer.

Obesity accelerates biological cardiovascular ageing by inducing structural and functional cardiac and vascular changes that mimic those of chronological ageing, independent of traditional risk factors.

Your heart ages based on how you treat it, not just your birth year. Obesity forces your heart to work harder and remodels it to look and function like an older, non-obese heart. Losing weight can reverse these changes, effectively turning back the biological clock of your cardiovascular system.

Central nervous system (CNS) activation of the Glucose-dependent Insulinotropic Polypeptide Receptor (GIPR) is required for the synergistic weight loss observed with dual GIPR/GLP-1R agonists.

If you are using a GLP-1 medication for weight loss or diabetes and struggle with side effects or plateauing results, newer dual-acting medications (targeting both GIP and GLP-1 receptors) may offer better weight loss with potentially fewer gastrointestinal side effects. This is because these drugs work on brain pathways that suppress appetite and may reduce the nausea often caused by older GLP-1-only drugs. Consult your doctor about whether a dual-agonist is appropriate for your metabolic health.

Liraglutide-induced weight loss is significantly attenuated in individuals consuming high-carbohydrate diets when hepatic FGF21 signaling is absent, indicating that FGF21 mediates the appetite-suppressing effects of GLP-1 receptor agonists specifically in the context of high carbohydrate intake.

If you are using a GLP-1 receptor agonist like liraglutide, your weight loss results may be suboptimal if you consume a high-carbohydrate diet. This is because the drug relies on a hormone called FGF21 to help suppress appetite, and this hormone is most effective at reducing food intake when carbohydrates are present. To maximize weight loss, consider reducing your carbohydrate intake, as this may enhance the drug's ability to engage the FGF21 pathway and promote greater weight reduction.

GLP-1R signaling primarily occurs through the Gαs/cAMP pathway, leading to insulin secretion, but also involves Gαq and β-arrestin pathways which contribute to receptor internalization and other metabolic effects.

GLP-1 drugs work by activating specific pathways in the body. The main pathway increases insulin when blood sugar is high. Other pathways help with receptor recycling and may contribute to other effects like cell survival.

Non-POMC neurons, specifically GABAergic neurons, mediate leptin's direct effects on energy balance and food intake, influencing POMC neurons indirectly.

This suggests that treatments targeting only POMC neurons may fail to reduce appetite. Future therapies might need to target GABAergic neurons or other non-POMC pathways to effectively manage obesity via leptin signaling.

POMC neurons expressing the glucagon-like peptide 1 receptor (Glp1r) are a distinct subpopulation from those expressing the leptin receptor (Lepr), and Glp1r-expressing POMC neurons may regulate energy balance.

This heterogeneity explains why broad activation of POMC neurons might have mixed results. Targeted therapies might need to distinguish between Lepr-expressing (glucose) and Glp1r-expressing (energy balance) subsets.